Daily Endocrinology Research Analysis
Today’s top endocrinology papers span diabetes care and cardiometabolic prevention: a joint Endocrine Society/ESE guideline addresses preexisting diabetes management across the reproductive continuum; a 46,992-participant cohort shows first-trimester insulin resistance indices—especially TyG-BMI—improve gestational diabetes prediction; and a meta-analysis of 25 RCTs quantifies GLP-1RA cardiovascular benefits with actionable numbers needed to treat.
Summary
Today’s top endocrinology papers span diabetes care and cardiometabolic prevention: a joint Endocrine Society/ESE guideline addresses preexisting diabetes management across the reproductive continuum; a 46,992-participant cohort shows first-trimester insulin resistance indices—especially TyG-BMI—improve gestational diabetes prediction; and a meta-analysis of 25 RCTs quantifies GLP-1RA cardiovascular benefits with actionable numbers needed to treat.
Research Themes
- Diabetes and pregnancy management
- Cardiovascular risk reduction with incretin-based therapies
- Early risk stratification using simple biochemical indices
Selected Articles
1. Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.
This joint Endocrine Society/ESE guideline, developed using GRADE and systematic reviews, issues practice recommendations across preconception, pregnancy, and postpartum care for individuals with preexisting diabetes. Key suggestions include universal pregnancy-intention screening, contraception when pregnancy is undesired, GLP-1RA cessation before conception, device-enabled glucose management (CGM, hybrid closed-loop for T1DM), risk-based early delivery, and structured postpartum endocrine care—while noting overall low to very low certainty of evidence.
Impact: Cross-society, GRADE-informed guidance shapes global standards for managing preexisting diabetes across the reproductive life course, integrating technology and risk-based obstetric decisions.
Clinical Implications: Implement routine pregnancy-intention screening, preconception contraception when appropriate, discontinue GLP-1RA before conception, consider CGM and hybrid closed-loop in T1DM pregnancy, avoid routine metformin add-on in insulin-treated T2DM, individualize early delivery timing based on risk, and ensure structured postpartum endocrine care.
Key Findings
- Screen for pregnancy intention at every relevant visit and recommend contraception if pregnancy is not desired.
- Discontinue GLP-1 receptor agonists before conception; avoid routine metformin add-on in insulin-treated T2DM during pregnancy.
- For PDM, either CGM or SMBG can be used; in pregnant T1DM, hybrid closed-loop pumps are suggested over pump+CGM without algorithm or MDI+CGM.
- Use standard pregnancy glucose targets rather than a single 24-hour CGM target <140 mg/dL.
- Prefer risk-based early delivery and ensure structured postpartum endocrine follow-up.
Methodological Strengths
- GRADE-based development with systematic literature reviews across 10 prioritized clinical questions.
- Multidisciplinary panel with patient representatives; consideration of values, costs, feasibility, and health equity.
Limitations
- Overall low to very low certainty evidence underpinning many recommendations, often indirect.
- Heterogeneity in available studies limits strength of guidance on nutrition, obesity management, and delivery timing.
Future Directions: Conduct RCTs to refine pregnancy glycemic targets and evaluate technology-enabled care; generate robust data on optimal nutrition, obesity therapies, and delivery timing; invest in implementation science for preconception care.
BACKGROUND: Preexisting diabetes (PDM) increases the risk of maternal and perinatal mortality and morbidity. Reduction of maternal hyperglycemia prior to and during pregnancy can reduce these risks. Despite compelling evidence that preconception care (PCC), which includes achieving strict glycemic goals, reduces the risk of congenital malformations and other adverse pregnancy outcomes, only a minority of individuals receive PCC. Suboptimal pregnancy outcomes demonstrated in real-world data highlight the need to further optimize prenatal glycemia. New evolving technology shows promise in helping to achieve that goal. Dysglycemia is not the only driver of poor pregnancy outcomes in PDM. The increasing impact of obesity on pregnancy outcomes underscores the importance of optimal nutrition and management of insulin sensitizing medications during prenatal care for PDM. OBJECTIVE: To provide recommendations for the care of individuals with PDM that lead to a reduction in maternal and neonatal adverse outcomes. METHODS: The Guideline Development Panel (GDP) composed of a multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 10 clinically relevant questions related to the care of individuals with diabetes before, during and after pregnancy.
2. Assessment of first-trimester insulin resistance indices for gestational diabetes mellitus: a prospective cohort study.
In 46,992 pregnancies, first-trimester insulin resistance surrogates were positively associated with subsequent GDM. TyG-BMI showed the strongest discrimination (AUC 0.651), and adding TyG-BMI to a demographic model improved AUC from 0.666 to 0.693. Associations were robust across subgroups and spline analyses.
Impact: This very large, prospectively collected cohort demonstrates that simple, readily available lipid-glucose indices—especially TyG-BMI—can enhance early GDM risk stratification beyond demographics.
Clinical Implications: Incorporate first-trimester TyG-BMI into early GDM risk assessment to triage intensified lifestyle counseling, glucose monitoring, or early diagnostic vigilance, recognizing modest but meaningful incremental predictive value.
Key Findings
- All four IR indices (TyG, TyG-BMI, AIP, METS-IR) measured in the first trimester were positively associated with GDM (p < 0.001).
- TyG-BMI provided the strongest discrimination (AUC 0.651) among indices.
- Adding TyG-BMI to a demographic model improved AUC from 0.666 to 0.693 for GDM prediction.
Methodological Strengths
- Very large prospective dataset (N=46,992) from a single tertiary center with standardized laboratory assessment.
- Robust statistical approach including logistic regression, restricted cubic splines, subgroup and ROC analyses.
Limitations
- Discrimination was modest (AUC ≤ 0.651), limiting solitary clinical use.
- Single-center Chinese cohort may limit generalizability; external validation is needed.
Future Directions: Validate TyG-BMI-enhanced models across diverse populations; integrate with clinical risk tools and CGM data; assess clinical impact of TyG-BMI-guided early interventions on maternal–neonatal outcomes.
BACKGROUND: Insulin resistance (IR) is a significant factor in gestational diabetes mellitus (GDM) development. The triglyceride-glucose (TyG) index, triglyceride-glucose body mass index (TyG-BMI), atherogenic index of plasma (AIP), and metabolic score for insulin resistance (METS-IR) are simple and reliable surrogates for assessing IR, but their predictive potential for GDM remains unexplored. METHODS: Data from 46,992 singleton pregnancies delivered at Beijing Obstetrics and Gynecology Hospital between 2018 and 2022 were prospectively collected. IR indices were calculated using first-trimester blood lipid and glucose measurements. Participants were classified into GDM and non-GDM groups based on oral glucose tolerance test (OGTT) results at 24-28 weeks.
3. Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.
Across 25 RCTs (109,846 participants), GLP-1RAs reduced MI (RR 0.86; NNT 207), cardiovascular mortality (RR 0.87; NNT 170), MACE (RR 0.87; NNT 67), and stroke (RR 0.88; NNT 335). Higher BMI predicted greater MI risk reduction. Gastrointestinal adverse events increased (RR 1.55; NNTH 9).
Impact: Provides clinically actionable NNT/NNTH alongside efficacy estimates across ASCVD outcomes, supporting broader use of GLP-1RAs in prevention, including patients without T2DM.
Clinical Implications: Consider GLP-1RAs for ASCVD prevention—particularly in higher-BMI populations—while counseling on GI tolerability; use NNT/NNTH to inform shared decision-making and population-level planning.
Key Findings
- GLP-1RAs reduced MI risk (RR 0.86) with NNTB 207 over ~3.5 years.
- Cardiovascular mortality, MACE, and stroke were reduced (RRs 0.87, 0.87, 0.88; NNTB 170, 67, 335).
- Gastrointestinal adverse events increased (RR 1.55; NNTH 9), and higher BMI predicted greater MI risk reduction.
Methodological Strengths
- Meta-analysis of randomized trials with large aggregate sample and prespecified outcomes.
- Reported clinically meaningful NNT/NNTH; random-effects modeling and moderator analysis (BMI).
Limitations
- Heterogeneity across trials and GLP-1RA agents; lack of individual patient data.
- Safety reporting varied; GI events prominent, long-term tolerability and adherence not fully captured.
Future Directions: Head-to-head comparisons across GLP-1RAs, phenotype-driven selection (e.g., by BMI), and pragmatic trials in primary prevention populations; integrate patient-reported outcomes on tolerability.
BACKGROUND: Glucagon like peptide-1 receptor agonist (GLP-1RA) use in individuals with high atherosclerotic cardiovascular disease (ASCVD) risk reduces major adverse cardiovascular events (MACE). However, its clinical impact, in terms of numbers needed to treat (NNT), efficacy and safety profile in reducing the risk of myocardial infarction (MI) and the individual ASCVD constituents remain unclear. METHODS: Electronic databases, Medline and Embase were reviewed for randomized trials from inception to 29 May 2025. Risk-reduction effect of GLP-1RA were pooled using pairwise meta-analysis with random-effects model. The primary outcome was MI, and secondary outcomes were the individual ASCVD constituents. RESULTS: 109,846 patients from 25 unique studies were included. Over a follow-up duration of 3.48 ± 1.51 (1.55 to 5.47) years, GLP-1RA reduced the risk of total MI (RR: 0.86, p < 0.01), with numbers needed to benefit (NNTB) of 207 to prevent one event of MI. Higher body mass index was associated with greater MI risk reduction (β: -0.09, p = 0.03) in GLP-1RA users. GLP-1RA reduced cardiovascular mortality (RR: 0.87, p < 0.01, NNTB 170), MACE (RR: 0.87, p < 0.01, NNTB 67) and stroke (RR: 0.88, p < 0.01, NNTB 335) compared to placebo. GLP-1RA commonly resulted in gastrointestinal side-effects amongst other systems (RR: 1.55, p < 0.01, NNTH 9). CONCLUSION: GLP-1RA reduced the risk of MI, stroke, cardiovascular mortality and MACE in a broad range of patients with and without T2DM and/or prior ASCVD, supporting its role in ASCVD prevention, especially in the cohort with high BMI.